Willmann S - Search Results

1

Development of a paediatric population-based model of the pharmacokinetics of rivaroxaban.

Willmann S, Becker C, Burghaus R, Coboeken K, Edginton A, Lippert J, Siegmund HU, Thelen K, Mück W. Willmann S, et al. Clin Pharmacokinet. 2014 Jan;53(1):89-102. doi: 10.1007/s40262-013-0090-5. Clin Pharmacokinet. 2014. PMID: 23912563 Free PMC article. Clinical Trial.

2

A physiological model for the estimation of the fraction dose absorbed in humans.

Willmann S, Schmitt W, Keldenich J, Lippert J, Dressman JB. Willmann S, et al. J Med Chem. 2004 Jul 29;47(16):4022-31. doi: 10.1021/jm030999b. J Med Chem. 2004. PMID: 15267240

3

Application of physiology-based pharmacokinetic and pharmacodynamic modeling to individualized target-controlled propofol infusions.

Edginton AN, Schmitt W, Willmann S. Edginton AN, et al. Among authors: willmann s. Adv Ther. 2006 Jan-Feb;23(1):143-58. doi: 10.1007/BF02850355. Adv Ther. 2006. PMID: 16644615

4

A mechanistic approach for the scaling of clearance in children.

Edginton AN, Schmitt W, Voith B, Willmann S. Edginton AN, et al. Among authors: willmann s. Clin Pharmacokinet. 2006;45(7):683-704. doi: 10.2165/00003088-200645070-00004. Clin Pharmacokinet. 2006. PMID: 16802850

5

From physicochemistry to absorption and distribution: predictive mechanistic modelling and computational tools.

Willmann S, Lippert J, Schmitt W. Willmann S, et al. Expert Opin Drug Metab Toxicol. 2005 Jun;1(1):159-68. doi: 10.1517/17425255.1.1.159. Expert Opin Drug Metab Toxicol. 2005. PMID: 16922658 Review.

6

Development and evaluation of a generic physiologically based pharmacokinetic model for children.

Edginton AN, Schmitt W, Willmann S. Edginton AN, et al. Among authors: willmann s. Clin Pharmacokinet. 2006;45(10):1013-34. doi: 10.2165/00003088-200645100-00005. Clin Pharmacokinet. 2006. PMID: 16984214

7

Development and validation of a physiology-based model for the prediction of oral absorption in monkeys.

Willmann S, Edginton AN, Dressman JB. Willmann S, et al. Pharm Res. 2007 Jul;24(7):1275-82. doi: 10.1007/s11095-007-9247-y. Epub 2007 Mar 21. Pharm Res. 2007. PMID: 17373575

8

Dynamically simulating the interaction of midazolam and the CYP3A4 inhibitor itraconazole using individual coupled whole-body physiologically-based pharmacokinetic (WB-PBPK) models.

Vossen M, Sevestre M, Niederalt C, Jang IJ, Willmann S, Edginton AN. Vossen M, et al. Among authors: willmann s. Theor Biol Med Model. 2007 Mar 26;4:13. doi: 10.1186/1742-4682-4-13. Theor Biol Med Model. 2007. PMID: 17386084 Free PMC article.

9

Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs.

Willmann S, Höhn K, Edginton A, Sevestre M, Solodenko J, Weiss W, Lippert J, Schmitt W. Willmann S, et al. J Pharmacokinet Pharmacodyn. 2007 Jun;34(3):401-31. doi: 10.1007/s10928-007-9053-5. Epub 2007 Mar 13. J Pharmacokinet Pharmacodyn. 2007. PMID: 17431751

10

Whole body physiologically-based pharmacokinetic models: their use in clinical drug development.

Edginton AN, Theil FP, Schmitt W, Willmann S. Edginton AN, et al. Among authors: willmann s. Expert Opin Drug Metab Toxicol. 2008 Sep;4(9):1143-52. doi: 10.1517/17425255.4.9.1143. Expert Opin Drug Metab Toxicol. 2008. PMID: 18721109 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

94 results

Search Page

Filters